Natural killer (NK; CD3−CD16+CD56+) lymphocytes (Figure 2E) decreased in all RA patients (12.99%) compared to HCs (15.7%), but the subgroups showed different patterns: ERA and flare-up (p < 0.05) subjects showed a reduction (11.26% and 8.46%, respectively), while remission patients presented a minor increase for these cells (17.96%). This evidence concerns the gene NCAM1 and rheumatoid arthritis.